<DOC>
	<DOCNO>NCT00894114</DOCNO>
	<brief_summary>This study design determine whether patient previously prim Ad5 MRKAd5 HIV-1 gag vaccine respond well boost ALVAC-HIV vaccine boost MKRAd5 HIV-1 gag vaccine .</brief_summary>
	<brief_title>A Study Safety , Tolerability Immunogenicity 1-Dose Regimen MRKAd5 HIV-1 Gag Vaccine Versus ALVAC_HIV Vaccine ( V520-019 )</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject previously enrol Merck HIV Vaccine study V520 Protocol 007 012 , receive complete 3dose regimen participation Subject good general health Subject infect HIV Subject agree donate blood first 52 week study Subject agree donate sperm first 12 week study Subject reproductive potential agrees use acceptable method birth control Week 12 study Subject administer immune globulin blood product 3 month prior receive study vaccination Subject vaccinate live virus vaccine past 30 day Subject vaccinate inactivated vaccine past 14 day Subject active medical disease Subject take daily require prescription drug Female subject pregnant , breastfeed expect conceive Subject positive HIV Subject use injection drug within past year Subject sexual partner infect HIV Subject sexual partner active injection drug user Subject treat diagnosed new sexually transmitted disease past 6 month Subject engage unprotected intercourse 2 person previous 6 month Subject engage protected intercourse 4 person previous 6 month Subject previously participate HIV vaccine clinical trial ( Merck V520 Protocols 007 012 ) Subject weigh less 110 lb . Subject recent history alcohol abuse Subject intend donate blood first 52 week trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>